Facing a weight crisis? New Zealand is grappling with a significant obesity problem, and the question of funding potentially life-changing medications is now at the forefront. Let's dive in.
New Zealand's Pharmac, the agency responsible for funding medicines, is currently seeking expert advice on whether to fund Wegovy, a weight loss medication. This decision is crucial, especially considering New Zealand's concerning statistics: the nation holds the third-highest adult obesity rate within the Organisation for Economic Co-operation and Development (OECD). Alarmingly, one in three adults over 15 are classified as obese, and the issue extends to children, with one in eight aged between 2-14 also falling into this category.
Pharmac has received two applications regarding Wegovy, also known as semaglutide, a GLP-1 receptor agonist designed for weight loss. The first application, submitted in September, targets individuals with established cardiovascular disease (e.g., those who have experienced a heart attack or stroke) and a Body Mass Index (BMI) of 27 or higher. The second application, filed in October, focuses on chronic weight management for individuals with a BMI of 30 or higher and at least one weight-related health issue.
Pharmac's director of advice and assessment, David Hughes, stated that guidance on this matter is expected later this month. He emphasized that expert advisors will evaluate the medicine's effectiveness compared to existing funded options, considering its impact on individuals, families, caregivers, and the broader healthcare system. Additionally, Pharmac is also assessing an application to fund Saxenda (liraglutide) for people with very high BMIs.
Across the Tasman Sea, Australia has already taken action. Australia announced that Wegovy will be subsidized, following its listing on the Pharmaceutical Benefits Scheme. This will significantly reduce the cost of the drug to AU$25 (NZ$29) per script, or AU$7.70 (NZ$9) for concession card holders.
But here's where it gets controversial... In New Zealand, Wegovy currently costs a hefty $459.99 per month. Associate Minister of Health David Seymour acknowledges the situation but cannot directly influence Pharmac's funding decisions. He is, however, encouraging them to explore budget efficiencies, suggesting that funding new drugs could potentially save taxpayer money in other areas.
Weight loss specialist Dr. Gerard McQuinlan strongly believes that funding Wegovy would ultimately save the taxpayer money. He points out the strong link between obesity and over 200 other diseases. For instance, the risk of developing Type 2 diabetes is about 12 times higher for those with obesity. He highlights that Type 2 diabetes alone costs the Ministry of Health approximately $2.1 billion annually.
Dr. McQuinlan doesn't foresee a shortage of Wegovy, especially once the pill form becomes available. He emphasizes that obesity is a chronic, relapsing, and progressive disease, with a 95% chance of weight regain if not managed through medication.
And this is the part most people miss... He explains that weight loss isn't just about willpower; it's a hormonal issue. Medications like Wegovy target the hormones that regulate hunger and satiety, helping people feel full.
What do you think? Do you agree that funding Wegovy could be a cost-effective solution in the long run? Share your thoughts in the comments below!
